Related Experiment Videos
Bucindolol: new hopes from reviewing past data
1Duke University Medical Center, Durham, NC, USA. Mona.Fiuzat@Duke.edu
Drugs of Today (Barcelona, Spain : 1998)
|October 21, 2011
Summary
Bucindolol hydrochloride, a novel beta-blocker, shows promise for treating chronic heart failure (CHF). Ongoing trials investigate its potential to reduce cardiovascular mortality and hospitalizations in specific patient groups.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Beta-blockers are essential for managing chronic heart failure (CHF).
- Bucindolol hydrochloride represents a new generation of beta-blocker therapy.
- Its efficacy in CHF treatment is under active investigation.
Purpose of the Study:
- To review the development and clinical application of bucindolol hydrochloride.
- To summarize the pharmacology and clinical trial data for bucindolol.
- To highlight its potential role in managing heart failure patients.
Main Methods:
- Review of existing literature on bucindolol hydrochloride.
- Analysis of data from completed and ongoing clinical trials.
- Pharmacological assessment of bucindolol's mechanism of action.
Main Results:
- Bucindolol hydrochloride is a fourth-generation beta-blocker.
- Two clinical trials have been completed, with a third in progress.
- The ongoing trial focuses on genotype-defined heart failure populations.
Conclusions:
- Bucindolol hydrochloride is a promising therapeutic agent for CHF.
- Further research is needed to confirm its long-term benefits.
- Its use in specific heart failure populations warrants continued investigation.
Related Concept Videos
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:21Drugs for Treatment of Constipation-Predominant IBS
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.